spacer
home > pmps > autumn 2009 > nasal drug delivery comes of age
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Nasal Drug Delivery Comes of Age

 

The well-established first generation of nasal sprays are those resulting in atomised liquid droplets for a topical effect in the nostrils and beyond. Decongestants and medication for rhinitis (hayfever) are well-established over-the-counter remedies in this category. They can suffer from droplet aggregation in the nostrils, running forward to reduce potential effectiveness, and patient irritation.

A number of relatively sophisticated liquid nasal devices have been introduced in recent years. These can be regarded as the second generation, enabling absorption of a therapeutic agent into the bloodstream (systemic) via inter-cellular tight junctions or transcellular migration, often using permeation enhancing excipients. While some droplets are large enough to aggregate in the nostrils, a low percentage can be small enough to pass all the way through the nasal passages to be either swallowed or inhaled into the lungs. Such low performance obviates the claim of the nasal route providing an action almost as fast as the intravenous route. Also, for liquids to dwell in the nasal passages, they need formulating with viscosity modifying compounds. Viscous formulations can complicate effective delivery of the dose, as appropriate spray technologies have to be developed, and patients trained in effective actuation of the device.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Ian Harrison is Chief Scientific Officer for Alchemy Healthcare. Following degrees in pharmaceutical science, Ian managed a teaching hospital pharmacy and lectured in clinical pharmacology. He was a consultant to the pharmaceutical industry until becoming CSO of the company he founded. After initial work on liquid nasal delivery, his focus has been redirected by the potential for dry powder delivery.

Steve Nichols is an independent consultant who specialises in OINDP development. He has 27 years’ experience in the industry, working on a wide range of products and devices for the global market place. More recently, he has concentrated on novel delivery and powder formulation technologies. He is a member of the EP Inhalanda working group and founder of the European Pharmaceutical Aerosol Group.

spacer
Ian Harrison
spacer
spacer
spacer
Steve Nichols
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

TrialScope Announces Partnership with Greater Gift

JERSEY CITY, NJ – May 14, 2019 – TrialScope, the global leader in clinical trial transparency, disclosure compliance and patient engagement solutions, has partnered with Greater Gift to donate vaccines to children in need.
More info >>

White Papers
 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement